Clinical Trials Browser

Lymphoma, B-Cell, Marginal Zone × tafasitamab × 90 days × Clear all

NCT04680052 2025-12-22

InMIND

Phase 3 Active not recruiting

654 enrolled 40 charts 1 FDA

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone